Kala Bio, INC. 8-K Filing

FAQ

Key Financial Figures

• $0.001 — nge on which registered Common Stock, $0.001 par value per share KALA The Nasdaq
• $375,000 — ertible loan in the aggregate amount of $375,000. Pursuant to the terms of the Convertib
• $6.0 million — s for aggregate gross proceeds of up to $6.0 million. Pursuant to the Securities Purchase Ag
• $2 — per Series AA Preferred Share equal to $2.00, for aggregate gross proceeds of $1.
• $1.8 million — $2.00, for aggregate gross proceeds of $1.8 million. The closing for the Series AA Preferre

Filing Documents

• kalabio_8k.htm (8-K) — 39KB
• 0001829126-25-010037.txt ( ) — 201KB
• kala-20251216.xsd (EX-101.SCH) — 3KB
• kala-20251216_lab.xml (EX-101.LAB) — 33KB
• kala-20251216_pre.xml (EX-101.PRE) — 22KB
• kalabio_8k_htm.xml (XML) — 3KB

08

Item 5.08. Shareholder Director Nominations . To the extent applicable, the information set forth below under Item 8.01 of this Current Report on Form 8-K "Notice of Annual Meeting" is incorporated by reference into this Item 5.08. Item 8.01. Other Events. Notice of Annual Meeting The Board of Directors of the Company has established January 30, 2026 as the date of the Company's next annual meeting of stockholders (the "Annual Meeting"). The Company plans to publish additional details regarding the exact time, location and matters to be voted on at the Annual Meeting in the Company's proxy statement for the Annual Meeting. Because the date of the Annual Meeting will change by more than 30 calendar days from the anniversary date of the Company's last annual meeting of stockholders, the Company has set a deadline for the receipt of stockholder proposals submitted pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended ("Rule 14a-8") for inclusion in the Company's proxy materials relating to the Annual Meeting. In order for a proposal under Rule 14a-8 to be timely, it must be received by the Company's Secretary at the principal executive offices of the Company by December 27, 2025, which the Company has determined to be a reasonable time before the Company's proxy materials are due to be printed and sent. Such proposals must also comply with the Company's Third Amended and Restated By-Laws (the "By-Laws") and the rules of the Securities and Exchange Commission regarding the inclusion of stockholder proposals in proxy materials, and any such proposal may be omitted if not in compliance with applicable requirements. The address of the Company's principal executive offices is 1167 Massachusetts Avenue, Arlington, Massachusetts 02476. Stockholders wishing to nominate a director or propose matters to be considered at the Annual Meeting in the manner contemplated by the By-Laws must submit timely notice to the Company in order for such matters

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. KALA BIO, INC. Date: December 16, 2025 By: /s/ David Lazar David Lazar Chief Executive Officer 3

View Full Filing

View this 8-K filing on SEC EDGAR